guest ::
| Home > Publications Database > Specific viral antibodies associate with anti-NMDAR encephalitis after herpes simplex encephalitis. > print |
| Home > Publications Database > Specific viral antibodies associate with anti-NMDAR encephalitis after herpes simplex encephalitis. > print |
| 001 | 280960 | ||
| 005 | 20250918102644.0 | ||
| 024 | 7 | _ | |a 10.1016/j.bbi.2025.106073 |2 doi |
| 024 | 7 | _ | |a pmid:40803454 |2 pmid |
| 024 | 7 | _ | |a 0889-1591 |2 ISSN |
| 024 | 7 | _ | |a 1090-2139 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01042 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 150 |
| 100 | 1 | _ | |a Kreye, Jakob |0 P:(DE-2719)2811468 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Specific viral antibodies associate with anti-NMDAR encephalitis after herpes simplex encephalitis. |
| 260 | _ | _ | |a Orlando, Fla. [u.a.] |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1756886450_1280 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Herpes simplex encephalitis (HSE) patients may develop secondary anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (NMDARE), associated with worsened long-term neurological outcome. Immunosuppressive treatment can limit NMDAR autoantibody-mediated pathology, but early predictive biomarkers for the risk of NMDARE are lacking. In a multicenter study, we performed unbiased antibody reactome profiling using Phage ImmunoPrecipitation Sequencing (PhIP-Seq). HSE patients with secondary NMDARE (n = 13) versus those without (n = 10) showed enhanced antibody responses against HSV-1, but not HSV-2, which comprised specific antibodies to five peptides of the HSV-1 UL42 and UL48 proteins. A score of these signature CSF antibodies identified HSE patients with secondary NMDARE with a sensitivity of 75%, a specificity of > 99%, a positive predictive value of 90%, a negative predictive value of > 97% and an odds ratio (OR) of 209 (CI: 28 - 1,582) across all individuals in this study, and with similar performance values in serum (>66%, >99%, >88%, >96%, OR 307 (15 - 6,089)). These signature antibodies represent a promising biomarker to identify HSE patients at risk for NMDARE development. In NMDARE patients without a history of HSE and in MS patients, no disease-associated HSV antibody reactivity patterns were detected. Furthermore, we introduced the Multiplexed Index Calculations of the Antibody Reactome (MICAR) metric to characterize proteomic targets of compartment-specific antibody responses, an approach that is applicable in neuroimmunology and other compartmentalized disease states. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Antibody reactome |2 Other |
| 650 | _ | 7 | |a Encephalitis |2 Other |
| 650 | _ | 7 | |a HSE |2 Other |
| 650 | _ | 7 | |a HSV |2 Other |
| 650 | _ | 7 | |a Intrathecal synthesis |2 Other |
| 650 | _ | 7 | |a MICAR |2 Other |
| 650 | _ | 7 | |a NMDAR |2 Other |
| 650 | _ | 7 | |a PhIP-Seq |2 Other |
| 700 | 1 | _ | |a Morgenlander, William R |b 1 |
| 700 | 1 | _ | |a Thakar, Manjusha |b 2 |
| 700 | 1 | _ | |a Schulte-Frankenfeld, Poul M |b 3 |
| 700 | 1 | _ | |a Schott, Sarah |b 4 |
| 700 | 1 | _ | |a Bünger, Isabel |b 5 |
| 700 | 1 | _ | |a Kornau, Hans-Christian |0 P:(DE-2719)2811900 |b 6 |u dzne |
| 700 | 1 | _ | |a Angkeow, Julia W |b 7 |
| 700 | 1 | _ | |a Jayaraman, Sahana |b 8 |
| 700 | 1 | _ | |a Otto, Carolin |b 9 |
| 700 | 1 | _ | |a Hahn, Wiebke |b 10 |
| 700 | 1 | _ | |a Lewerenz, Jan |b 11 |
| 700 | 1 | _ | |a Thaler, Franziska S |b 12 |
| 700 | 1 | _ | |a Korporal-Kuhnke, Mirjam |b 13 |
| 700 | 1 | _ | |a Melzer, Nico |b 14 |
| 700 | 1 | _ | |a Dargvainiene, Justina |b 15 |
| 700 | 1 | _ | |a Bien, Christian G |b 16 |
| 700 | 1 | _ | |a Kohlie, Rose |b 17 |
| 700 | 1 | _ | |a Lattwein, Erik |b 18 |
| 700 | 1 | _ | |a Schmitz, Dietmar |0 P:(DE-2719)2810725 |b 19 |u dzne |
| 700 | 1 | _ | |a Calabresi, Peter A |b 20 |
| 700 | 1 | _ | |a Pardo, Carlos A |b 21 |
| 700 | 1 | _ | |a Prüss, Harald |0 P:(DE-2719)2810931 |b 22 |u dzne |
| 700 | 1 | _ | |a Ruprecht, Klemens |b 23 |
| 700 | 1 | _ | |a Benjamin Larman, H. |b 24 |
| 773 | _ | _ | |a 10.1016/j.bbi.2025.106073 |g Vol. 130, p. 106073 - |0 PERI:(DE-600)1462491-6 |p 106073 |t Brain, behavior and immunity |v 130 |y 2025 |x 0889-1591 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/280960/files/DZNE-2025-01042.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/280960/files/DZNE-2025-01042%20SUP.docx |
| 856 | 4 | _ | |u https://pub.dzne.de/record/280960/files/DZNE-2025-01042.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:280960 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2811468 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2811900 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 19 |6 P:(DE-2719)2810725 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 22 |6 P:(DE-2719)2810931 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-19 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b BRAIN BEHAV IMMUN : 2022 |d 2024-12-19 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRAIN BEHAV IMMUN : 2022 |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-19 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-19 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-19 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-19 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-19 |
| 920 | 1 | _ | |0 I:(DE-2719)1810003 |k AG Prüß |l Autoimmune Encephalopathies |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1810004 |k AG Schmitz |l Network Dysfunction |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1810003 |
| 980 | _ | _ | |a I:(DE-2719)1810004 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|